Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease
3 other identifiers
observational
9,999
1 country
1
Brief Summary
The purpose of this study is to characterize the molecular and cell biology of the tumor cells in lymphoma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 1999
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 1999
CompletedFirst Submitted
Initial submission to the registry
November 9, 2006
CompletedFirst Posted
Study publicly available on registry
November 10, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2099
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2099
December 24, 2025
December 1, 2025
100.1 years
November 9, 2006
December 17, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Collection of tumor tissue to characterize the molecular and cell biology of tumor cells in lymphoma.
The study will continue indefinitely.
Eligibility Criteria
Any type of NHL or Hodgkin's disease.
You may qualify if:
- Diagnosis of Hodgkin's disease or non-Hodgkin's lymphoma, any cellular classification, any stage, any grade.
- Adult or pediatric patients receiving lymph node excision for purposes other than cancer therapy (i.e. tonsillectomy, sleep apnea).
- A routine procedure for tissue collection is planned.
- Ability to understand and the willingness to sign a written informed consent.
You may not qualify if:
- Patients without NHL or Hodgkin's disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Stanford Universitylead
- The Leukemia and Lymphoma Societycollaborator
- Biospect Inccollaborator
Study Sites (1)
Stanford University School of Medicine
Stanford, California, 94305, United States
Related Publications (2)
Roschewski M, Kurtz DM, Westin JR, Lynch RC, Gopal AK, Alig SK, Sworder BJ, Cherng HJ, Kuffer C, Blair D, Brown K, Goldstein JS, Schultz A, Close S, Chabon JJ, Diehn M, Wilson WH, Alizadeh AA. Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma. J Clin Oncol. 2025 Dec;43(34):3652-3661. doi: 10.1200/JCO-25-01534. Epub 2025 Aug 13.
PMID: 40802906DERIVEDKurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Levy R, Newman AM, Duhrsen U, Huttmann A, Meignan M, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2018 Oct 1;36(28):2845-2853. doi: 10.1200/JCO.2018.78.5246. Epub 2018 Aug 20.
PMID: 30125215DERIVED
Biospecimen
tumor tissue
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ronald Levy, MD
Stanford University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 9, 2006
First Posted
November 10, 2006
Study Start
January 1, 1999
Primary Completion (Estimated)
January 1, 2099
Study Completion (Estimated)
January 1, 2099
Last Updated
December 24, 2025
Record last verified: 2025-12